In a recent development, stocks of Novavax Inc (NASDAQ: NVAX) jumped 8.2% yesterday following the Food and Drug Administration’s (FDA) approval of its improved COVID-19 vaccine. However, it’s worth noting that in pre-market trading, the stock experienced a slight dip and is 6% down at the time of writing.

The Roll-Out of Novavax Updated Shots

As highlighted in a recent report, Novavax is gearing up to make its updated COVID-19 vaccine available at thousands of locations in the coming days.

The FDA’s decision, which came late Tuesday, has been met with enthusiasm from investors and health experts alike. Novavax has been at the forefront of vaccine research and development, and this latest approval solidifies its position as a key player in the global vaccination effort.

One of the critical aspects of this approval is the extension of the age group eligible for the Novavax booster. The vaccine is now approved for individuals aged 12 and older, providing a broader range of protection for adolescents and young adults.

The updated vaccine specifically addresses the XBB.1.5 subvariant of the Omicron variant, which has raised concerns due to its potential to evade immunity conferred by earlier versions of the vaccine.

While this subvariant currently accounts for only a small percentage of sequenced cases in the United States, it has demonstrated concerning properties in lab testing against other strains. Novavax’s ability to adapt quickly to these emerging threats is a testament to the flexibility and innovation of its vaccine platform.

Comparing Novavax’s Vaccine to Pfizer and Moderna

In contrast to Novavax’s stock increase, shares of Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) exhibited muted movement in late trading, suggesting that investors may be closely watching Novavax’s entry into the market and assessing its potential impact on the competitive landscape.

However, it is worth noting that Novavax employs a different approach to vaccine development compared to the mRNA vaccines produced by Pfizer and Moderna. While Pfizer and Moderna’s updated vaccines also received FDA approval last month, Novavax’s technology is based on proteins rather than messenger RNA.

This diversity in vaccine platforms is advantageous as it allows for a more comprehensive approach to tackling the virus and its variants. Despite the FDA’s approval, there have been reports of limited vaccine supplies for Novavax, Pfizer, and Moderna.

The high demand for booster shots and the need to cover a broader age range have put pressure on vaccine manufacturers to ramp up production. Moderna, for example, announced that it is shipping additional supplies daily to meet the increasing demand for its vaccine.

Moderna’s CEO Stephane Bancel expressed enthusiasm for combination vaccines, emphasizing their ability to enhance the consumer and provider experience, boost compliance with public health recommendations, and offer value to healthcare systems.

The move to Phase 3 development for combination respiratory vaccines signifies Moderna’s commitment to addressing the seasonal threat posed by respiratory viruses effectively.

next

Business News, Market News, News, Stocks, Wall Street

Novavax Inc (NASDAQ: NVAX) recently experienced a stock surge following several key announcements by the biotech company. On Tuesday, NVAX jumped 30% on news that Novavax had promising new Covid and flu vaccine data. Furthermore, the Maryland-based company also announced cost-cutting measures, including a 25% staff downsizing.

Novavax’s announcements offer a ray of hope to investors after the preceding quarter when the company doubted its ability to remain competitive. At the time, vaccine developers refrained from providing full-year guidance due to the uncertainty of its future. However, it now banks on sweeping cost control actions and new influenza and Covid vaccines to remain profitable. The Novavax stock surge also came along with the company’s first-quarter report.

Novavax Stock Surge Propelled by Bright Optics in Latest Quarterly Report

In its Q1 2023 earnings report, the company forecasted full-year sales of between $1.4 billion and $1.6 billion.

On Tuesday, Novavax shares closed at $9.52, ending with a market capitalization of approximately $821 million. The company’s share price is down by more than 7% year-to-date.

In the first-quarter report, Novavax President and Chief Executive Officer John C. Jacobs touched on the company’s agenda, saying:

“Today, we outlined significant measures intended to reduce spending, extend our cash runway, and operate more efficiently. Combined with our focus on revenue generation from Nuvaxovid and management of our current liabilities, these measures should strengthen our cash position and our potential for the long-term growth and stability of Novavax.”

Jacobs added that Novavax also made “significant progress on other key priorities”, including efforts to deliver updated Covid vaccines for the Fall season. Furthermore, the biotech platform’s chief executive also pointed out:

“We [recently] announced positive Phase 2 data that we believe supports the further development of our combination COVID-influenza, standalone influenza, and high-dose COVID vaccines.”

After 35 years of business, Novavax’s Covid antidote remains its only commercially available product.

In a media session, a Novavax spokesperson noted that its staff downsizing would affect nearly 400 full-time equivalent employees. The shakeups also involve strengthening the firm’s facilities and infrastructure. These measures may help Novavax become more profitable and likely see a potential stock surge.

Although Jacobs admitted that reducing the company’s workforce is a “difficult decision”, the CEO deemed the action necessary. He says downsizing helps Novavax better align its infrastructure and scale to “the endemic Covid opportunity”. In conclusion, Jacobs opined that the biotech firm is encouraged by the progress made in the last quarter to take on substantial challenges ahead. Furthermore, the Novavax chief executive added that the company remains determined to continue executing its top priorities.

Novavax Q1 2023 at a Glance

For the first quarter of 2023, Novavax realized total revenue of $81 million, which was way off the $704 million recorded in Q1 2022. The company ascribed the considerable gulf in earnings to an “emerging seasonal demand pattern for Covid vaccines”. Furthermore, Novavax explained that Q1 2023 product sales include a $65 million revenue reversal from doses delivered last year that are scheduled for future replacement.

Meanwhile, the first-quarter cost of sales for 2023 came in at $34 million versus $15 million in the first three months of 2022. However, the latest sales cost included $20 million for surplus, outdated, or expired inventory and firm purchase commitment losses.

next

Business News, Market News, News, Stocks, Wall Street